Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement

Mazzone, Peter J.; Sears, Catherine R.; Arenberg, Douglas A.; Gaga, Mina; Gould, Michael K.; Massion, Pierre P.; Nair, Vish S.; Powell, Charles A.; Silvestri, Gerard A.; Vachani, Anil; Wiener, Renda Soylemez

doi:10.1164/rccm.201708-1678st

Cited by 115 publications

(79 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among these, studies have discovered AABs associated with lung cancer that have the potential to distinguish malignant disease from CT‐positive benign nodules . In Europe, EarlyCDT‐Lung, which contains a panel of seven AABs (p53, NY‐ESO‐1, GBU4‐5, CAGE, SOX2, HuD, and MAGE A4), was confirmed to have 87% specificity and 41% sensitivity .…”

Section: Discussionmentioning

confidence: 98%

The diagnostic value of a seven‐autoantibody panel and a nomogram with a scoring table for predicting the risk of non–small‐cell lung cancer

Wang

Zhuang

et al. 2020

Cancer Science

View full text Add to dashboard Cite

The early detection of non-small-cell lung cancer (NSCLC) remains a common concern. The aim of our study was to validate the diagnostic value of a seven-autoantibody (7-AAB) panel compared with radiological diagnosis for NSCLC. We constructed a nomogram and a scoring table based on the 7-AAB panel's result to predict the risk of NSCLC. We prospectively enrolled 268 patients who presented with radiological lesions and underwent both the 7-AAB panel test and pathological diagnosis by surgical resection. A comparison between the 7-AAB panel and radiological diagnosis was performed. A nomogram and a scoring table based on the 7-AAB panel's result to predict the risk of NSCLC were constructed and internally validated. The 7-AAB panel test had a specificity of 90.2% and a positive predictive value (PPV) of 92.7%, which were significantly higher than those of the radiological diagnosis. The 7-AAB panel also showed a preferable sensitivity in patients with early-stage disease. Seven factors, including the 7-AAB panel results, were integrated into the nomogram. For more convenient application, we formulated a scoring table based on the nomogram.The area under the receiver operating characteristic curve was 0.840 and 0.860 in the training group and validation group, respectively, which was higher than that using the 7-AAB panel or radiological diagnosis alone. This study reveals that our 7-AAB panel has clinical value in the diagnosis of NSCLC. The utility of our nomogram and the scoring table indicated that they have the potential to assist clinicians in avoiding unnecessary treatment or needless follow-up. K E Y W O R D Sautoantibodies, CT scanning, early diagnosis, nomogram, non-small-cell lung cancer R E FE R E N C E S

show abstract

Section: Discussionmentioning

confidence: 98%

The diagnostic value of a seven‐autoantibody panel and a nomogram with a scoring table for predicting the risk of non–small‐cell lung cancer

Wang

Zhuang

et al. 2020

Cancer Science

View full text Add to dashboard Cite

show abstract

“…e underlying biological and molecular mechanisms of lung cancer are gradually being understood over the past decades [3]. e molecular biomarkers may improve the early lung cancer detection [4]. Furthermore, traditional chemotherapy that is based on histopathology is replaced by the individualized precision treatment which is based on carcinogenic factors [5].…”

Section: Introductionmentioning

confidence: 99%

Identification of Three lncRNAs as Potential Predictive Biomarkers of Lung Adenocarcinoma

Jin

Song

Chen

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Lung cancer is the most common cancer and the most common cause of cancer-related death worldwide. However, the molecular mechanism of its development is unclear. It is imperative to identify more novel biomarkers. Methods. Two datasets (GSE70880 and GSE113852) were downloaded from the Gene Expression Omnibus (GEO) database and used to identify the differentially expressed genes (DEGs) between lung cancer tissues and normal tissues. Then, we constructed a competing endogenous RNA (ceRNA) network and a protein-protein interaction (PPI) network and performed gene ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and survival analyses to identify potential biomarkers that are related to the diagnosis and prognosis of lung cancer. Results. A total of 41 lncRNAs and 805 mRNAs were differentially expressed in lung cancer. The ceRNA network contained four lncRNAs (CLDN10-AS1, SFTA1P, SRGAP3-AS2, and ADAMTS9-AS2), 21 miRNAs, and 48 mRNAs. Functional analyses revealed that the genes in the ceRNA network were mainly enriched in cell migration, transmembrane receptor, and protein kinase activity. mRNAs DLGAP5, E2F7, MCM7, RACGAP1, and RRM2 had the highest connectivity in the PPI network. Immunohistochemistry (IHC) demonstrated that mRNAs DLGAP5, MCM7, RACGAP1, and RRM2 were upregulated in lung adenocarcinoma (LUAD). Survival analyses showed that lncRNAs CLDN10-AS1, SFTA1P, and ADAMTS9-AS2 were associated with the prognosis of LUAD. Conclusion. lncRNAs CLDN10-AS1, SFTA1P, and ADAMTS9-AS2 might be the biomarkers of LUAD. For the first time, we confirmed the important role of lncRNA CLDN10-AS1 in LUAD.

show abstract

“…Still, the 2.5-year timeframe in the fourth round of NELSON resulted in a significant increase in interval cancers and more cancers detected at a later stage [36]. Blood and breath biomarkers may have a role in a more risk-stratified approach and in tailoring the most beneficial LCS protocol; however, there is no current evidence to support their utility in screening [37].…”

Section: Participation In Lcs Trialsmentioning

confidence: 99%

ESR/ERS statement paper on lung cancer screening

et al. 2020

Self Cite

View full text Add to dashboard Cite

In Europe, lung cancer ranks third among the most common cancers, remaining the biggest killer. Since the publication of the first European Society of Radiology and European Respiratory Society joint white paper on lung cancer screening (LCS) in 2015, many new findings have been published and discussions have increased considerably. Thus, this updated expert opinion represents a narrative, non-systematic review of the evidence from LCS trials and description of the current practice of LCS as well as aspects that have not received adequate attention until now. Reaching out to the potential participants (persons at high risk), optimal communication and shared decision-making will be key starting points. Furthermore, standards for infrastructure, pathways and quality assurance are pivotal, including promoting tobacco cessation, benefits and harms, overdiagnosis, quality, minimum radiation exposure, definition of management of positive screen results and incidental findings linked to respective actions as well as cost-effectiveness. This requires a multidisciplinary team with experts from pulmonology and radiology as well as thoracic oncologists, thoracic surgeons, pathologists, family doctors, patient representatives and others. The ESR and ERS agree that Europe's health systems need to adapt to allow citizens to benefit from organised pathways, rather than unsupervised initiatives, to allow early diagnosis of lung cancer and reduce the mortality rate. Now is the time to set up and conduct demonstration programmes focusing, among other points, on methodology, standardisation, tobacco cessation, education on healthy lifestyle, cost-effectiveness and a central registry.

show abstract

Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement

Cited by 115 publications

References 69 publications

The diagnostic value of a seven‐autoantibody panel and a nomogram with a scoring table for predicting the risk of non–small‐cell lung cancer

The diagnostic value of a seven‐autoantibody panel and a nomogram with a scoring table for predicting the risk of non–small‐cell lung cancer

Identification of Three lncRNAs as Potential Predictive Biomarkers of Lung Adenocarcinoma

ESR/ERS statement paper on lung cancer screening

Contact Info

Product

Resources

About